These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

7374 related articles for article (PubMed ID: 12941039)

  • 21. Efficacy of unfractionated heparin, low molecular weight heparin and both combined for releasing total and free tissue factor pathway inhibitor.
    Altman R; Scazziota A; Rouvier J
    Haemostasis; 1998; 28(5):229-35. PubMed ID: 10420071
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Low Molecular Weight Heparin Tinzaparin Attenuates Platelet Activation in Terms of Metastatic Niche Formation by Coagulation-Dependent and Independent Pathways.
    Gockel LM; Ponert JM; Schwarz S; Schlesinger M; Bendas G
    Molecules; 2018 Oct; 23(11):. PubMed ID: 30356007
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anticoagulant pharmacodynamics of tinzaparin following 175 iu/kg subcutaneous administration to healthy volunteers.
    Barrett JS; Hainer JW; Kornhauser DM; Gaskill JL; Hua TA; Sprogel P; Johansen K; van Lier JJ; Knebel W; Pieniaszek HJ
    Thromb Res; 2001 Feb; 101(4):243-54. PubMed ID: 11248285
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Role of Tinzaparin in Oncology.
    Dimakakos EP; Vathiotis I; Syrigos K
    Clin Appl Thromb Hemost; 2018 Jul; 24(5):697-707. PubMed ID: 29088922
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tinzaparin sodium: a review of its pharmacology and clinical use in the prophylaxis and treatment of thromboembolic disease.
    Cheer SM; Dunn CJ; Foster R
    Drugs; 2004; 64(13):1479-502. PubMed ID: 15212562
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protamine neutralization of intravenous and subcutaneous low-molecular-weight heparin (tinzaparin, Logiparin). An experimental investigation in healthy volunteers.
    Holst J; Lindblad B; Bergqvist D; Garre K; Nielsen H; Hedner U; Ostergaard PB
    Blood Coagul Fibrinolysis; 1994 Oct; 5(5):795-803. PubMed ID: 7865687
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative efficacy of different low-molecular-weight heparins (LMWHs) and drug interactions with LMWH: implications for management of vascular disorders.
    Mousa SA
    Semin Thromb Hemost; 2000; 26 Suppl 1():39-46. PubMed ID: 11011805
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-metastasis efficacy and safety of non-anticoagulant heparin derivative versus low molecular weight heparin in surgical pancreatic cancer models.
    Alyahya R; Sudha T; Racz M; Stain SC; Mousa SA
    Int J Oncol; 2015 Mar; 46(3):1225-31. PubMed ID: 25530018
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Binding between heparin and the integrin VLA-4.
    Schlesinger M; Simonis D; Schmitz P; Fritzsche J; Bendas G
    Thromb Haemost; 2009 Nov; 102(5):816-22. PubMed ID: 19888514
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low molecular weight heparins prevent thrombin-induced thrombo-embolism in mice despite low anti-thrombin activity. Evidence that the inhibition of feed-back activation of thrombin generation confers safety advantages over direct thrombin inhibition.
    Momi S; Nasimi M; Colucci M; Nenci GG; Gresele P
    Haematologica; 2001 Mar; 86(3):297-302. PubMed ID: 11255277
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacodynamic considerations in the selection of dosage of tinzaparin for various indications: experimental studies in primates.
    Jeske W; Fareed J
    Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():41-7. PubMed ID: 15085465
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery.
    Bara L; Planes A; Samama MM
    Br J Haematol; 1999 Feb; 104(2):230-40. PubMed ID: 10050702
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tissue distribution of the low molecular weight heparin, tinzaparin, following administration to rats by the oral route.
    Hiebert LM; Wice SM; Ping T
    Biomed Pharmacother; 2004; 58(6-7):372-80. PubMed ID: 15271419
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibitory effect of C-reactive protein on the release of tissue factor pathway inhibitor from human endothelial cells: reversal by low molecular weight heparin.
    Mousa SA
    Int Angiol; 2006 Mar; 25(1):10-3. PubMed ID: 16520718
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of VLA-4 binding for experimental melanoma metastasis and its inhibition by heparin.
    Schlesinger M; Roblek M; Ortmann K; Naggi A; Torri G; Borsig L; Bendas G
    Thromb Res; 2014 May; 133(5):855-62. PubMed ID: 24636486
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bedside monitoring of anticoagulation in chronic haemodialysis patients treated with tinzaparin.
    Pauwels R; Devreese K; Van Biesen W; Eloot S; Glorieux G; Vanholder R; Dhondt A
    Nephrol Dial Transplant; 2014 May; 29(5):1092-6. PubMed ID: 24366900
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thrombin generation post elective caesarean section: effect of low molecular weight heparin.
    Ismail SK; Norris L; Muttukrishna S; Higgins JR
    Thromb Res; 2012 Nov; 130(5):799-803. PubMed ID: 22365560
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment with modified heparins inhibits experimental metastasis formation and leads, in some animals, to long-term survival.
    Sciumbata T; Caretto P; Pirovano P; Pozzi P; Cremonesi P; Galimberti G; Leoni F; Marcucci F
    Invasion Metastasis; 1996; 16(3):132-43. PubMed ID: 9186548
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Laboratory analysis of blood samples from patients treated with tinzaparin.
    Hoppensteadt DA; Willows L; Leitz H; Nicolaides A; Fareed J
    Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():49-55. PubMed ID: 15085466
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tinzaparin. A review of its pharmacology and clinical potential in the prevention and treatment of thromboembolic disorders.
    Friedel HA; Balfour JA
    Drugs; 1994 Oct; 48(4):638-60. PubMed ID: 7528134
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 369.